Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts

Journal of Clinical Investigation

Volumn 122, Issue 5, 2012, Pages 1653-1666

  Moiani, Arianna ^a   Paleari, Ylenia ^a   Sartori, Daniela ^a   Mezzadra, Riccardo ^a   Miccio, Annarita ^b   Cattoglio, Claudia ^a,e   Cocchiarella, Fabienne ^b   Lidonnici, Maria Rosa ^a,c   Ferrari, Giuliana ^a,c   Mavilio, Fulvio ^a,b,d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d GÉNÉTHON   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; GAG PROTEIN; LENTIVIRUS VECTOR;

5' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ARTICLE; CELL CLONING; CELL CULTURE; CELL TYPE; GENE LOCUS; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN GENOME; LONG TERMINAL REPEAT; PRIORITY JOURNAL; REGULATOR GENE; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ALTERNATIVE SPLICING; BASE SEQUENCE; CELLS, CULTURED; GENES, REPORTER; GENOME, HUMAN; GREEN FLUORESCENT PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; INTRONS; LENTIVIRUS; LENTIVIRUS INFECTIONS; MOLECULAR SEQUENCE DATA; MUTANT CHIMERIC PROTEINS; PRIMARY CELL CULTURE; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA SPLICE SITES; RNA STABILITY; RNA, MESSENGER; TRANSGENES; VIRUS INTEGRATION;

EID: 84860594261     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61852     Document Type: Article

References (35)

1. Bushman F, et al. Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol. 2005;3(11):848-858. (Pubitemid 41693180)
2. Cattoglio C, et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood. 2007;110(6):1770-1778. (Pubitemid 47443887)
3. Cattoglio C, et al. High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood. 2010;116(25):5507-5517.
4. Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 2007;17(8):1186-1194. (Pubitemid 47204862)
5. Engelman A, Cherepanov P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog. 2008;4(3):e1000046.
6. Lewinski MK, et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2006;2(6):e60.
7. Aiuti A, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447-458.
8. Hacein-Bey-Abina S, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346(16):1185-1193. (Pubitemid 34984579)
9. Mavilio F, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006;12(12):1397-1402. (Pubitemid 44924498)
10. Cartier N, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326(5954):818-823.
11. Boztug K, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med. 2010;363(20):1918-1927.
12. Hacein-Bey-Abina S, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132- 3142.
13. Howe SJ, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9):3143-3150.
14. Krause D. Gene therapy for Wiskott-Aldrich syndrome: benefits and risks. The Hematologist. 2011;8(2):10.
15. Ott MG, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401-409.
16. Stein S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16(2):198-204.
17. Montini E, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24(6):687-696. (Pubitemid 43882120)
18. Maruggi G, et al. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol Ther. 2009;17(5):851-856.
19. Modlich U, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009;17(11):1919-1928.
20. Montini E, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest. 2009;119(4):964-975.
21. Almarza D, Bussadori G, Navarro M, Mavilio F, Larcher F, Murillas R. Risk assessment in skin gene therapy: viral-cellular fusion transcripts generated by proviral transcriptional read-through in keratinocytes transduced with self-inactivating lentiviral vectors. Gene Ther. 2011;18(7):674-681.
22. Nilsen TW, et al. c-erbB activation in ALV-induced erythroblastosis: novel RNA processing and promoter insertion result in expression of an aminotruncated EGF receptor. Cell. 1985;41(3):719-726. (Pubitemid 15243379)
23. Yang Q, Lucas A, Son S, Chang LJ. Overlapping enhancer/promoter and transcriptional termination signals in the lentiviral long terminal repeat. Retrovirology. 2007;4:4.
24. Cavazzana-Calvo M, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 2010;467(7313):318-322.
25. Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol. 1993;67(11):6365-6378. (Pubitemid 23309100)
26. Cattoglio C, et al. High-definition mapping of retroviral integration sites defines the fate of allogeneic T cells after donor lymphocyte infusion. PLoS One. 2010;5(12):e15688.
27. Recchia A, et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci U S A. 2006;103(5):1457-1462. (Pubitemid 43191187)
28. De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther. 2003;14(12):1193-1206. (Pubitemid 36930408)
29. Follenzi A, Sabatino G, Lombardo A, Boccaccio C, Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther. 2002;13(2):243-260. (Pubitemid 34164109)
30. Di Nunzio F, et al. Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors. Mol Ther. 2008;16(12):1977-1985.
31. Miccio A, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A. 2008;105(30):10547-10552.
32. Marktel S, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood. 2003;101(4):1290-1298. (Pubitemid 36182498)
33. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003;31(13):3568-3571. (Pubitemid 37442199)
34. The AST lab of Tel Aviv University. Splice Analyzer Tool. Tel Aviv University Web site. http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm. Accessed March 8, 2012.
35. Workman CT, Yin Y, Corcoran DL, Ideker T, Stormo GD, Benos PV. enoLOGOS: a versatile web tool for energy normalized sequence logos. Nucleic Acids Res. 2005;33(Web Server issue):W389-W392.